Tudor Investment Adds $4M in AbCellera Biologics Inc. ($ABCL)

Tudor Investment has increased its position in AbCellera Biologics Inc. (NasdaqGS: ABCL) by 26.6%, according to its latest 13F filing with the SEC. The firm added 477,479 shares, raising its total holdings to 2,273,489 shares valued at approximately $18 million. This move was reported as of May 15, 2026, and reflects Tudor Investment's growing confidence in the biotechnology company.

What Changed in Tudor Investment's AbCellera Biologics Position

Tudor Investment's recent filing reveals a 26.6% increase in its stake in AbCellera Biologics. The firm now holds 2,273,489 shares, up from 1,796,010 shares previously. The total value of its holdings in the company stands at around $18 million.

Other Institutional Activity in AbCellera Biologics

Several other institutional investors have also been active in AbCellera Biologics. Baker Bros. Advisors LP increased its holdings by 2,750,298 shares, ending with 30,275,938 shares valued at about $105.7 million. Two Sigma Investments, LP added 4,751,080 shares, bringing its total to 10,562,065 shares worth approximately $36.9 million, marking an 81.8% increase. TD Waterhouse Canada Inc. dramatically boosted its position by 9,542,247 shares, now holding 9,564,659 shares valued at $33.6 million. UBS Group AG also increased its stake by 2,269,643 shares, totaling 4,209,052 shares worth $14.7 million, a 117% rise.

AbCellera Biologics Inc. Stock Down 29.4%

Shares of AbCellera Biologics traded near $7.93 on Tuesday. The company has a market capitalization of about $2.25 billion. Despite its innovative focus, the firm has no meaningful P/E ratio due to its lack of profitability, as indicated by a forward P/E of -10.25. The stock's 52-week range spans from $2.75 to $7.40, with a 50-day moving average of $5.03 and a 200-day moving average of $4.31. AbCellera maintains a strong balance sheet with a current ratio of 14.05 and a quick ratio of 12.29.

Recent Earnings

AbCellera Biologics reported revenue of $79.2 million with a growth rate of 96.3%. However, the company posted a net margin of -181.7% and a return on equity of -14.7%, reflecting its current unprofitability. The next earnings release is expected on August 6, 2026.

Insider Buying and Selling at AbCellera Biologics Inc.

Recent insider activity at AbCellera Biologics includes several purchases on June 11, 2026. Insiders such as Michael Hayden, John Montalbano, and Stephen Quake each bought 111,701 shares. On June 3, 2026, CFO Andrew Booth sold 250,000 shares but also bought the same amount at an average price of $0.19. John Montalbano also purchased 20,000 shares at $4.77 on May 14, 2026.

Analysts Set New Price Targets

Analyst activity around AbCellera Biologics has been notable. On May 5, 2026, Cantor Fitzgerald initiated coverage with a 'buy' rating and a $7.00 price target. Similarly, Jones Trading initiated a 'buy' rating with an $11.00 target on April 10, 2026. The consensus among analysts is a 'strong buy', with an average target price of $10.43 based on seven opinions.

About AbCellera Biologics

AbCellera Biologics Inc. is a biotechnology company focused on discovering and developing antibody-based medicines for diseases with unmet medical needs. Headquartered in Vancouver, BC, the company is led by CEO Dr. Carl L.G. Hansen and employs 562 people. AbCellera collaborates with major firms like Eli Lilly and AbbVie to advance treatments for conditions such as autoimmune diseases and vasomotor symptoms.

Bottom Line

Tudor Investment's increased stake in AbCellera Biologics highlights growing institutional interest in the company. Investors track such filings to gauge institutional confidence in a stock. It's important to remember that these filings reflect past holdings as of the reporting period and may not represent the investor's current position.